[Federal Register Volume 76, Number 117 (Friday, June 17, 2011)]
[Notices]
[Page 35480]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-15025]


=======================================================================
-----------------------------------------------------------------------

NATIONAL AERONAUTICS AND SPACE ADMINISTRATION

[Notice (11-052)]


Notice of Intent To Grant Partially Exclusive License

AGENCY: National Aeronautics and Space Administration.

ACTION: Notice of intent to grant partially exclusive license.

-----------------------------------------------------------------------

SUMMARY: This notice is issued in accordance with 35 U.S.C. 209(e) and 
37 CFR 404.7(a)(1)(i). NASA hereby gives notice of its intent to grant 
a partially exclusive license in the United States to practice the 
inventions described and claimed in USPN 6,047,216, Endothelium 
Preserving Microwave Treatment For Atherosclerosis, NASA Case No. MSC-
22724-1, USPN 6,226,553, Endothelium Preserving Microwave Treatment For 
Atherosclerosis, NASA Case No. MSC-22724-2, USPN 6,223,086, Endothelium 
Preserving Microwave Treatment For Atherosclerosis, NASA Case No. MSC-
22724-3, and USPN 6,496,736, Endothelium Preserving Microwave Treatment 
For Atherosclerosis, NASA Case No. MSC-22724-5 to Meridian Health 
Systems, P.C., having its principal place of business in Los Angeles, 
California. The patent rights in these inventions have been assigned to 
the United States of America as represented by the Administrator of the 
National Aeronautics and Space Administration. The prospective 
partially exclusive license will comply with the terms and conditions 
of 35 U.S.C. 209 and 37 CFR 404.7.

DATES: The prospective partially exclusive license may be granted 
unless within fifteen (15) days from the date of this published notice, 
NASA receives written objections including evidence and argument that 
establish that the grant of the license would not be consistent with 
the requirements of 35 U.S.C. 209 and 37 CFR 404.7. Competing 
applications completed and received by NASA within fifteen (15) days of 
the date of this published notice will also be treated as objections to 
the grant of the contemplated partially exclusive license.
    Objections submitted in response to this notice will not be made 
available to the public for inspection and, to the extent permitted by 
law, will not be released under the Freedom of Information Act, 5 
U.S.C. 552.

ADDRESSES: Objections relating to the prospective license may be 
submitted to Patent Counsel, Office of Chief Counsel, 2101 NASA 
Parkway, Houston, Texas 77058, Mail Code AL; Phone (281) 483-3021; Fax 
(281) 483-6936.

FOR FURTHER INFORMATION CONTACT: Theodore U. Ro, Intellectual Property 
Attorney, Office of Chief Counsel, 2101 NASA Parkway, Houston, Texas 
77058, Mail Code AL; Phone (281) 244-7148; Fax (281) 483-6936. 
Information about other NASA inventions available for licensing can be 
found online at http://technology.nasa.gov/.

    Dated: June 13, 2011.
Richard W. Sherman,
Deputy General Counsel.
[FR Doc. 2011-15025 Filed 6-16-11; 8:45 am]
BILLING CODE